TR201901074T4 - MGlu2 reseptörlerinin negatif allosterik modülatörleri olarak 6,7-dihidropirazolo[1,5-a]pirazin-4(5h)-on bileşikleri ve bunların kullanımı. - Google Patents

MGlu2 reseptörlerinin negatif allosterik modülatörleri olarak 6,7-dihidropirazolo[1,5-a]pirazin-4(5h)-on bileşikleri ve bunların kullanımı. Download PDF

Info

Publication number
TR201901074T4
TR201901074T4 TR2019/01074T TR201901074T TR201901074T4 TR 201901074 T4 TR201901074 T4 TR 201901074T4 TR 2019/01074 T TR2019/01074 T TR 2019/01074T TR 201901074 T TR201901074 T TR 201901074T TR 201901074 T4 TR201901074 T4 TR 201901074T4
Authority
TR
Turkey
Prior art keywords
4alkyl
compound
group
disorders
pyrazine
Prior art date
Application number
TR2019/01074T
Other languages
English (en)
Turkish (tr)
Inventor
Alonso-De Diego Sergio-Alvar
Luc Maria Van Gool Michiel
Delgado-González Óscar
Ignacio Andrés-Gil Jose
Avelino Trabanco-Suárez Andrés
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of TR201901074T4 publication Critical patent/TR201901074T4/tr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41621,2-Diazoles condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TR2019/01074T 2014-08-01 2015-07-30 MGlu2 reseptörlerinin negatif allosterik modülatörleri olarak 6,7-dihidropirazolo[1,5-a]pirazin-4(5h)-on bileşikleri ve bunların kullanımı. TR201901074T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14179598 2014-08-01

Publications (1)

Publication Number Publication Date
TR201901074T4 true TR201901074T4 (tr) 2019-02-21

Family

ID=51257437

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/01074T TR201901074T4 (tr) 2014-08-01 2015-07-30 MGlu2 reseptörlerinin negatif allosterik modülatörleri olarak 6,7-dihidropirazolo[1,5-a]pirazin-4(5h)-on bileşikleri ve bunların kullanımı.

Country Status (34)

Country Link
US (3) US10005786B2 (enExample)
EP (1) EP3177623B1 (enExample)
JP (1) JP6662846B2 (enExample)
KR (1) KR102531689B1 (enExample)
CN (1) CN106573936B (enExample)
AR (1) AR101392A1 (enExample)
AU (1) AU2015295298B2 (enExample)
BR (1) BR112017001726A2 (enExample)
CA (1) CA2954093C (enExample)
CL (1) CL2017000192A1 (enExample)
CY (1) CY1121649T1 (enExample)
DK (1) DK3177623T3 (enExample)
EA (1) EA031087B1 (enExample)
ES (1) ES2708215T3 (enExample)
HR (1) HRP20181997T1 (enExample)
HU (1) HUE042871T2 (enExample)
IL (1) IL250298A0 (enExample)
JO (1) JOP20150179B1 (enExample)
LT (1) LT3177623T (enExample)
MA (1) MA39582B1 (enExample)
ME (1) ME03320B (enExample)
MX (1) MX376289B (enExample)
NZ (1) NZ728122A (enExample)
PH (1) PH12017500161B1 (enExample)
PL (1) PL3177623T3 (enExample)
PT (1) PT3177623T (enExample)
RS (1) RS58279B1 (enExample)
SG (1) SG11201700638YA (enExample)
SI (1) SI3177623T1 (enExample)
SM (1) SMT201900038T1 (enExample)
TR (1) TR201901074T4 (enExample)
TW (1) TWI696624B (enExample)
WO (1) WO2016016380A1 (enExample)
ZA (1) ZA201700759B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL279202B2 (en) 2014-01-21 2023-09-01 Janssen Pharmaceutica Nv Combinations containing positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic subtype 2 receptor and their use
CN109999025A (zh) 2014-01-21 2019-07-12 詹森药业有限公司 包括代谢型谷氨酸能受体亚型2的正别构调节物或正位激动剂的组合及其用途
JOP20150179B1 (ar) * 2014-08-01 2021-08-17 Janssen Pharmaceutica Nv مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
JOP20150177B1 (ar) 2014-08-01 2021-08-17 Janssen Pharmaceutica Nv مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
JP6861154B2 (ja) 2014-12-03 2021-04-21 ヤンセン ファーマシューティカ エヌ.ベー. 放射標識されたmGluR2 PETリガンド
EP3227295B1 (en) 2014-12-03 2019-02-20 Janssen Pharmaceutica NV 6,7-dihydropyrazolo[1,5- ]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglu2 receptors
PL3389727T3 (pl) 2015-12-18 2021-02-08 Janssen Pharmaceutica Nv RADIOZNAKOWANE LIGANDY mGluR2/3 DO PET
CA3003962A1 (en) 2015-12-18 2017-06-22 Janssen Pharmaceutica Nv Radiolabelled mglur2/3 pet ligands
JP2020011902A (ja) * 2016-10-26 2020-01-23 大日本住友製薬株式会社 縮環ピロール誘導体およびその医薬用途
CN107298682B (zh) * 2017-06-29 2019-03-01 天津药明康德新药开发有限公司 一种4,5,6,7-四氢吡唑并[1,5-a]吡嗪-2-甲酸乙酯的合成方法
ES2991283T3 (es) 2017-11-24 2024-12-03 Sumitomo Pharma Co Ltd Derivado de 6,7-dihidropirazolo[1,5-a]pirazinona y aplicación médica del mismo
WO2019145214A1 (en) * 2018-01-26 2019-08-01 Recordati Industria Chimica E Farmaceutica S.P.A TRIAZOLE, IMIDAZOLE AND PYRROLE CONDENSED PIPERAZINE DERIVATIVES AND THEIR USE AS MODULATORS OF mGlu5 RECEPTORS
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0756200B1 (en) 1995-07-26 1999-11-10 Konica Corporation Silver halide color photographic light-sensitive material
DE19653647A1 (de) 1996-12-20 1998-06-25 Hoechst Ag Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
US6482821B2 (en) 1996-12-20 2002-11-19 Hoechst Aktiengellschaft Vitronectin receptor antagonists, their preparation and their use
US6754375B1 (en) 1999-07-16 2004-06-22 Packard Bioscience Company Method and system for interactively developing at least one grid pattern and computer-readable storage medium having a program for executing the method
US6831074B2 (en) 2001-03-16 2004-12-14 Pfizer Inc Pharmaceutically active compounds
US20030114448A1 (en) 2001-05-31 2003-06-19 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
WO2005061507A1 (en) 2003-12-16 2005-07-07 Pfizer Products Inc. Bicyclic pyrazol-4-one cannabinoid receptor ligands and uses thereof
WO2005123738A1 (en) 2004-06-21 2005-12-29 F.Hoffmann-La Roche Ag Pyrrazolo-pyrimidine derivatives
WO2006030847A1 (ja) 2004-09-17 2006-03-23 Dainippon Sumitomo Pharma Co., Ltd. 新規二環性ピラゾール誘導体
DE102004054665A1 (de) 2004-11-12 2006-05-18 Bayer Cropscience Gmbh Substituierte bi- und tricyclische Pyrazol-Derivate Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
AU2006212457B2 (en) 2005-02-11 2011-04-14 F. Hoffmann-La Roche Ag Pyrazolo-pyrimidine derivatives as mGLuR2 antagonists
AU2006226669B2 (en) 2005-03-23 2011-12-08 F. Hoffmann-La Roche Ag Acetylenyl-pyrazolo-pvrimidine derivatives as mGluR2 antagonists
US7998959B2 (en) 2006-01-12 2011-08-16 Incyte Corporation Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
WO2008001115A2 (en) 2006-06-29 2008-01-03 Astex Therapeutics Limited Pharmaceutical combinations of 1-cyclopropyl-3- [3- (5-m0rphoolin-4-ylmethyl-1h-benzoimidazol-2-yl) -lh-1-pyrazol- 4-yl] -urea
WO2008141249A1 (en) 2007-05-10 2008-11-20 Acadia Pharmaceuticals Inc. Imidazol (1,2-a)pyridines and related compounds with activity at cannabinoid cb2 receptors
EP2085390A1 (en) 2008-01-31 2009-08-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Labelled analogues of halobenzamides as multimodal radiopharmaceuticals and their precursors
US9446995B2 (en) 2012-05-21 2016-09-20 Illinois Institute Of Technology Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions
US8222424B2 (en) 2008-03-24 2012-07-17 Novartis Ag Arylsulfonamide-based matrix metalloprotease inhibitors
EP2327704A4 (en) 2008-08-29 2012-05-09 Shionogi & Co RING-CONDENSED AZOL DERIVATIVE WITH PI3K-INHIBITING EFFECT
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
NZ596078A (en) 2009-05-12 2013-06-28 Janssen Pharmaceuticals Inc 1,2,4-TRIAZOLO [4,3-a] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS
JP2013537210A (ja) 2010-09-16 2013-09-30 ノバルティス アーゲー 17α−ヒドロキシラーゼ/C17,20−リアーゼ阻害剤
CA2815120A1 (en) 2010-11-08 2012-05-18 Jose Ignacio Andres-Gil Radiolabelled mglur2 pet ligands
EP2651222A4 (en) 2010-12-17 2014-04-30 Univ Vanderbilt BICYCLIC TRIAZOL AND PYRAZOLLACTAME AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
WO2012172093A1 (en) 2011-06-17 2012-12-20 Merz Pharma Gmbh & Co. Kgaa Dihydroindolizine derivate as metabotropic glutamate receptor modulators
CN103930422A (zh) 2011-07-19 2014-07-16 无限药品股份有限公司 杂环化合物及其用途
AR088218A1 (es) 2011-07-19 2014-05-21 Infinity Pharmaceuticals Inc Compuestos heterociclicos utiles como inhibidores de pi3k
RU2610262C2 (ru) * 2011-11-03 2017-02-08 Мерк Шарп И Доум Корп. ХИНОЛИНКАРБОКСАМИДНЫЕ И ХИНОЛИНКАРБОНИТРИЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ mGLuR2-НЕГАТИВНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ, КОМПОЗИЦИИ И ИХ ПРИМЕНЕНИЕ
KR101607793B1 (ko) 2011-11-25 2016-03-30 닛본 덴끼 가부시끼가이샤 셀 식별자 할당 방법, 기지국, 보수 서버, 및 이동 통신 시스템
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US20130281397A1 (en) 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
EP2666775A1 (en) 2012-05-21 2013-11-27 Domain Therapeutics Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
WO2013192350A1 (en) * 2012-06-20 2013-12-27 Vanderbilt University Substituted bicyclic aralkyl pyrazole lactam analogs as allosteric modulators of mglur5 receptors
WO2013192347A1 (en) 2012-06-20 2013-12-27 Vanderbilt University Substituted bicyclic cycloalkyl pyrazole lactam analogs as allosteric modulators of mglur5 receptors
CN104736156A (zh) * 2012-06-20 2015-06-24 范德比尔特大学 作为mglur5受体变构调节剂的取代的双环烷氧基吡唑类似物
KR20150070187A (ko) 2012-10-23 2015-06-24 에프. 호프만-라 로슈 아게 자폐 장애의 치료를 위한 mglu2/3 길항제
CN103772686B (zh) 2012-10-26 2015-01-07 苏州雷纳药物研发有限公司 一种两亲性嵌段共聚物及其制备方法、以及该共聚物与抗肿瘤药物形成的胶束载药系统
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JOP20150177B1 (ar) 2014-08-01 2021-08-17 Janssen Pharmaceutica Nv مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
US10017514B2 (en) 2014-08-01 2018-07-10 Janssen Pharmaceutica Nv 6,7-dihydropyrazolo[1,5-α]pyrazin-4(5H)-one compounds and their use as negative allosteric modulators of mGluR2 receptors
JO3601B1 (ar) 2014-08-01 2020-07-05 Janssen Pharmaceutica Nv مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
RU2708391C2 (ru) 2014-08-01 2019-12-06 Янссен Фармацевтика Нв 6,7-дигидропиразоло[1,5-а]пиразин-4(5h)-оновые соединения и их применение в качестве отрицательных аллостерических модуляторов рецепторов mglur2
JOP20150179B1 (ar) * 2014-08-01 2021-08-17 Janssen Pharmaceutica Nv مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
JP6861154B2 (ja) 2014-12-03 2021-04-21 ヤンセン ファーマシューティカ エヌ.ベー. 放射標識されたmGluR2 PETリガンド
EP3227295B1 (en) 2014-12-03 2019-02-20 Janssen Pharmaceutica NV 6,7-dihydropyrazolo[1,5- ]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglu2 receptors
CA3003962A1 (en) 2015-12-18 2017-06-22 Janssen Pharmaceutica Nv Radiolabelled mglur2/3 pet ligands
PL3389727T3 (pl) 2015-12-18 2021-02-08 Janssen Pharmaceutica Nv RADIOZNAKOWANE LIGANDY mGluR2/3 DO PET

Also Published As

Publication number Publication date
MX376289B (es) 2025-03-07
MA39582A1 (fr) 2018-06-29
US20170217972A1 (en) 2017-08-03
CN106573936B (zh) 2020-01-07
JP6662846B2 (ja) 2020-03-11
LT3177623T (lt) 2019-02-11
PL3177623T3 (pl) 2019-04-30
PH12017500161B1 (en) 2022-05-18
CL2017000192A1 (es) 2017-07-28
EP3177623B1 (en) 2018-11-07
CA2954093A1 (en) 2016-02-04
US10512646B2 (en) 2019-12-24
SMT201900038T1 (it) 2019-02-28
ME03320B (me) 2019-10-20
MX2017001452A (es) 2017-05-09
PH12017500161A1 (en) 2017-06-28
WO2016016380A8 (en) 2017-01-19
US20180256569A1 (en) 2018-09-13
JP2017522340A (ja) 2017-08-10
EA201692540A1 (ru) 2017-05-31
CA2954093C (en) 2022-11-29
ZA201700759B (en) 2018-12-19
PT3177623T (pt) 2019-02-01
BR112017001726A2 (pt) 2017-11-21
CN106573936A (zh) 2017-04-19
SI3177623T1 (sl) 2019-01-31
CY1121649T1 (el) 2020-07-31
US20200121677A1 (en) 2020-04-23
KR102531689B1 (ko) 2023-05-10
WO2016016380A1 (en) 2016-02-04
AU2015295298B2 (en) 2019-07-11
MA39582B1 (fr) 2019-10-31
HRP20181997T1 (hr) 2019-01-25
SG11201700638YA (en) 2017-02-27
TW201617346A (zh) 2016-05-16
TWI696624B (zh) 2020-06-21
KR20170031247A (ko) 2017-03-20
HUE042871T2 (hu) 2019-07-29
DK3177623T3 (en) 2019-02-25
NZ728122A (en) 2022-07-29
EA031087B1 (ru) 2018-11-30
ES2708215T3 (es) 2019-04-09
US10005786B2 (en) 2018-06-26
AU2015295298A1 (en) 2017-01-12
JOP20150179B1 (ar) 2021-08-17
EP3177623A1 (en) 2017-06-14
RS58279B1 (sr) 2019-03-29
AR101392A1 (es) 2016-12-14
IL250298A0 (en) 2017-03-30

Similar Documents

Publication Publication Date Title
TR201901074T4 (tr) MGlu2 reseptörlerinin negatif allosterik modülatörleri olarak 6,7-dihidropirazolo[1,5-a]pirazin-4(5h)-on bileşikleri ve bunların kullanımı.
AU2015295313B2 (en) 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one compounds and their use as negative allosteric modulators of mGluR2 receptors
CA2994717A1 (en) Heterocyclic compounds useful as modulators of tnf alpha
AU2015295300B2 (en) 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mGluR2 receptors
CA2954222C (en) 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglur2 receptors
KR102531693B1 (ko) 6,7―디히드로피라졸로[1,5―a]피라진―4(5H)―온 화합물 및 MGLUR2 수용체의 음성 알로스테릭 조절제로서의 그 용도
CA2967153A1 (en) 6,7-dihydropyrazolo[1,5-.alpha.]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglur2 receptors
RS59707B1 (sr) Derivati karbazola
HK1236925A1 (en) 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglur2 receptors
HK1242307A1 (en) 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglur2 receptors
HK1242307B (zh) 6,7-二氢吡唑并[1,5-a]吡嗪-4(5h)-酮化合物及其作为mglur2受体的负向别构调节剂的用途